A novel series of indazole-/indole-based glucagon receptor antagonists (original) (raw)
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus
Mary Didiuk
Bioorganic & Medicinal Chemistry Letters, 2013
View PDFchevron_right
Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes
Mari Candelore
Journal of Medicinal Chemistry, 2012
View PDFchevron_right
In Silico Identification of Novel Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus
Pritish Kumar
Enzyme Engineering, 2015
View PDFchevron_right
Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist
Mari Candelore
PLoS ONE, 2012
View PDFchevron_right
Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
Huba Kalasz
The open medicinal chemistry journal, 2014
View PDFchevron_right
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Guoqiang Jiang, Mari Candelore
Diabetes, 2004
View PDFchevron_right
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Jennifer Estall
Current Pharmaceutical Design, 2006
View PDFchevron_right
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
Thazha Prakash
European Journal of Internal Medicine, 2014
View PDFchevron_right
A Review of Practical Issues on the Use of Glucagon- Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
芳瑩 廖
View PDFchevron_right
Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes
Owais Khan
Current Opinion in Endocrinology & Diabetes, 2005
View PDFchevron_right
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Edoardo Mannucci
Diabetes Therapy, 2015
View PDFchevron_right
Novel strategies for the pharmacological management of type 2 diabetes
Angela Bulotta
Trends in Pharmacological Sciences, 2004
View PDFchevron_right
Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models
Andrew Bowler
Diabetologia, 2022
View PDFchevron_right
Identification of a novel conformationally constrained glucagon receptor antagonist
Mary Didiuk
Bioorganic & Medicinal Chemistry Letters, 2014
View PDFchevron_right
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
Xiaoxiong Wei
Diabetes, obesity & metabolism, 2016
View PDFchevron_right
Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
Johan Granados Vega
Ces Medicina, 2018
View PDFchevron_right
Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-hydroxybenzoic Acid [1-(2,3,5,6-Tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide
John May
Journal of Medicinal Chemistry, 2002
View PDFchevron_right
Therapeutic molecules against type 2 diabetes: What we have and what are we expecting
Ashwini Kumar, SUDHANSHU BHARTI
View PDFchevron_right
Discovery of potent, orally active benzimidazole glucagon receptor antagonists
Guoqiang Jiang, Mari Candelore
Bioorganic & Medicinal Chemistry Letters, 2008
View PDFchevron_right
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
jiayu liao
Proceedings of the National Academy of Sciences, 2007
View PDFchevron_right
Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes
Mohamed Al-omar
Saudi medical journal, 2005
View PDFchevron_right
Overview of Glucagon-like Peptide-1 Receptor Agonists
Joan Grant
Home healthcare now
View PDFchevron_right
Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus
Sonam Grover
BMC bioinformatics, 2014
View PDFchevron_right
Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: Assessment of composite end-points.
Ryota Usui, Daisuke Yabe
View PDFchevron_right
Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents
Kiran Shah
Bioorganic & Medicinal Chemistry Letters, 2012
View PDFchevron_right
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
Fabian Tibaldi
Diabetes, Obesity and Metabolism, 2011
View PDFchevron_right
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
Nicole Barucci, Kevin Clairmont
Journal of Endocrinology, 2007
View PDFchevron_right
The Glucagon Receptor as a Drug Target - a Witches’ Brew of Eye of Newt (Peptides) and Toe of Frog (Receptors)
Derek Nunez
Diabetes, Obesity and Metabolism
View PDFchevron_right
des His 1, des Phe 6, Glu 9]glucagon amide: A newly designed “pure” glucagon antagonist
Clinton David
Bioorganic & Medicinal Chemistry Letters, 1995
View PDFchevron_right